Malignant T cell (null)

Malignant T cells are neoplastic T lymphocytes that have undergone monoclonal transformation and are the central malignant population in T-cell lymphomas, most notably cutaneous T-cell lymphoma (CTCL; including mycosis fungoides and Sézary syndrome) and various subtypes of peripheral T-cell lymphoma. These cells retain many features of normal T cells, including surface markers (such as CD3, CD4, CD8, or CD30), but are defined by unregulated proliferation, abnormal survival, and frequently carry recurrent genetic alterations in genes involved in T-cell signaling (e.g., TCR pathway), cell cycle control (e.g., TP53, CDKN2A), epigenetic regulation (e.g., TET2, DNMT3A), and apoptosis (e.g., FAS). There is substantial molecular heterogeneity, with molecular oncogenic drivers and gene expression programs underlying subgroups and prognosis, but "malignant T cell" refers to a cell population, not a specific molecular entity or canonical target[1][2][5][6][8][9][10]. "Malignant T-cells" is a generic, non-canonical designation for neoplastic T-lymphocytes, not a molecular target. No standard abbreviation, unifying molecular classification, or drug interaction list exists for this entity. For structured molecular targeting, a more specific surface marker, signaling molecule, or genetic alteration should be specified[1][5][8][10].

Other names

Malignant T lymphocyteNeoplastic T cellLymphoma T cell

null